Physician profile
Na Shen
NPI 1225268824
$3,972.32
in general payments reported to CMS, 2019-2025
16 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $49.27 · 2021: $287 · 2022: $584 · 2023: $1,912 · 2024: $211 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,803 · Food and Beverage: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,802.70 |
| Food and Beverage | $602.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,675.42 | 2019-2025 | Wegovy |
| Dexcom, INC. | $167.77 | 2019-2022 | |
| Nevro Corp. | $148.37 | 2022 | |
| Opko Pharmaceuticals, LLC | $140.12 | 2019 | |
| Phathom Pharmaceuticals, INC. | $124.98 | 2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $120.94 | 2021 | |
| Shionogi INC | $118.92 | 2021 | |
| Redhill Biopharma INC. | $114.21 | 2022 | |
| Sanofi-Aventis U.S. LLC | $83.79 | 2019-2022 | |
| Medtronic Minimed, INC. | $80.50 | 2019 | |
| Tandem Diabetes Care, INC. | $66.60 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $50.00 | 2024 | Zepbound |
| Rhythm Pharmaceuticals, INC. | $31.50 | 2021 | |
| Recordati_rare_diseases_inc. | $17.74 | 2020 | |
| Insulet Corporation | $15.95 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Na Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.